Literature DB >> 24089484

Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism.

Lara J Duffney1, Jing Wei, Jia Cheng, Wenhua Liu, Katharine R Smith, Josef T Kittler, Zhen Yan.   

Abstract

Shank3, which encodes a scaffolding protein at glutamatergic synapses, is a genetic risk factor for autism. In this study, we examined the impact of Shank3 deficiency on the NMDA-type glutamate receptor, a key player in cognition and mental illnesses. We found that knockdown of Shank3 with a small interfering RNA (siRNA) caused a significant reduction of NMDAR-mediated ionic or synaptic current, as well as the surface expression of NR1 subunits, in rat cortical cultures. The effect of Shank3 siRNA on NMDAR currents was blocked by an actin stabilizer, and was occluded by an actin destabilizer, suggesting the involvement of actin cytoskeleton. Since actin dynamics is regulated by the GTPase Rac1 and downstream effector p21-activated kinase (PAK), we further examined Shank3 regulation of NMDARs when Rac1 or PAK was manipulated. We found that the reducing effect of Shank3 siRNA on NMDAR currents was mimicked and occluded by specific inhibitors for Rac1 or PAK, and was blocked by constitutively active Rac1 or PAK. Immunocytochemical data showed a strong reduction of F-actin clusters after Shank3 knockdown, which was occluded by a PAK inhibitor. Inhibiting cofilin, the primary downstream target of PAK and a major actin depolymerizing factor, prevented Shank3 siRNA from reducing NMDAR currents and F-actin clusters. Together, these results suggest that Shank3 deficiency induces NMDAR hypofunction by interfering with the Rac1/PAK/cofilin/actin signaling, leading to the loss of NMDAR membrane delivery or stability. It provides a potential mechanism for the role of Shank3 in cognitive deficit in autism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089484      PMCID: PMC3787498          DOI: 10.1523/JNEUROSCI.1175-13.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  86 in total

1.  Rapid dendritic remodeling in the developing retina: dependence on neurotransmission and reciprocal regulation by Rac and Rho.

Authors:  W T Wong; B E Faulkner-Jones; J R Sanes; R O Wong
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

Review 2.  Trafficking of NMDA receptors.

Authors:  Robert J Wenthold; Kate Prybylowski; Steve Standley; Nathalie Sans; Ronald S Petralia
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

3.  Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.

Authors:  Adam Shutes; Cercina Onesto; Virginie Picard; Bertrand Leblond; Fabien Schweighoffer; Channing J Der
Journal:  J Biol Chem       Date:  2007-10-11       Impact factor: 5.157

4.  Regulation of dendritic growth and remodeling by Rho, Rac, and Cdc42.

Authors:  R Threadgill; K Bobb; A Ghosh
Journal:  Neuron       Date:  1997-09       Impact factor: 17.173

Review 5.  Signaling between the actin cytoskeleton and the postsynaptic density of dendritic spines.

Authors:  A Rao; A M Craig
Journal:  Hippocampus       Date:  2000       Impact factor: 3.899

6.  Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex.

Authors:  Eunice Y Yuen; Zhen Yan
Journal:  J Neurosci       Date:  2009-01-14       Impact factor: 6.167

7.  Phosphatidylinositol (4,5)-bisphosphate regulation of N-methyl-D-aspartate receptor channels in cortical neurons.

Authors:  Madhuchhanda Mandal; Zhen Yan
Journal:  Mol Pharmacol       Date:  2009-09-21       Impact factor: 4.436

Review 8.  PAK signalling in neuronal physiology.

Authors:  Patricia Kreis; Jean-Vianney Barnier
Journal:  Cell Signal       Date:  2008-11-12       Impact factor: 4.315

Review 9.  ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease.

Authors:  Tobias M Boeckers; Jürgen Bockmann; Michael R Kreutz; Eckart D Gundelfinger
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

10.  SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism.

Authors:  C M Durand; J Perroy; F Loll; D Perrais; L Fagni; T Bourgeron; M Montcouquiol; N Sans
Journal:  Mol Psychiatry       Date:  2011-05-24       Impact factor: 15.992

View more
  60 in total

1.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

Review 2.  The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.

Authors:  Donald C Rojas
Journal:  J Neural Transm (Vienna)       Date:  2014-04-22       Impact factor: 3.575

3.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

4.  Sensitivity to isoflurane anesthesia increases in autism spectrum disorder Shank3+/∆c mutant mouse model.

Authors:  Changsheng Li; Michele Schaefer; Christy Gray; Ya Yang; Orion Furmanski; Sufang Liu; Paul Worley; C David Mintz; Feng Tao; Roger A Johns
Journal:  Neurotoxicol Teratol       Date:  2016-11-14       Impact factor: 3.763

5.  Early Correction of N-Methyl-D-Aspartate Receptor Function Improves Autistic-like Social Behaviors in Adult Shank2-/- Mice.

Authors:  Changuk Chung; Seungmin Ha; Hyojin Kang; Jiseok Lee; Seung Min Um; Haidun Yan; Ye-Eun Yoo; Taesun Yoo; Hwajin Jung; Dongwon Lee; Eunee Lee; Seungjoon Lee; Jihye Kim; Ryunhee Kim; Yonghan Kwon; Woohyun Kim; Hyosang Kim; Lara Duffney; Doyoun Kim; Won Mah; Hyejung Won; Seojung Mo; Jin Yong Kim; Chae-Seok Lim; Bong-Kiun Kaang; Tobias M Boeckers; Yeonseung Chung; Hyun Kim; Yong-Hui Jiang; Eunjoon Kim
Journal:  Biol Psychiatry       Date:  2018-10-09       Impact factor: 13.382

6.  Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers.

Authors:  Andrea L Pappas; Alexandra L Bey; Xiaoming Wang; Mark Rossi; Yong Ho Kim; Haidun Yan; Fiona Porkka; Lara J Duffney; Samantha M Phillips; Xinyu Cao; Jin-Dong Ding; Ramona M Rodriguiz; Henry H Yin; Richard J Weinberg; Ru-Rong Ji; William C Wetsel; Yong-Hui Jiang
Journal:  JCI Insight       Date:  2017-10-19

7.  Novel Shank3 mutant exhibits behaviors with face validity for autism and altered striatal and hippocampal function.

Authors:  Thomas C Jaramillo; Haley E Speed; Zhong Xuan; Jeremy M Reimers; Christine Ochoa Escamilla; Travis P Weaver; Shunan Liu; Irina Filonova; Craig M Powell
Journal:  Autism Res       Date:  2016-08-05       Impact factor: 5.216

8.  Reversal of social deficits by subchronic oxytocin in two autism mouse models.

Authors:  Brian L Teng; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; James J Crowley; Lorinda K Baker; Beverly H Koller; Cort A Pedersen; Michael B Jarstfer; Sheryl S Moy
Journal:  Neuropharmacology       Date:  2015-12-31       Impact factor: 5.250

Review 9.  Monogenic mouse models of autism spectrum disorders: Common mechanisms and missing links.

Authors:  S W Hulbert; Y-H Jiang
Journal:  Neuroscience       Date:  2015-12-28       Impact factor: 3.590

10.  Histone deacetylase inhibitor MS-275 restores social and synaptic function in a Shank3-deficient mouse model of autism.

Authors:  Kaijie Ma; Luye Qin; Emmanuel Matas; Lara J Duffney; Aiyi Liu; Zhen Yan
Journal:  Neuropsychopharmacology       Date:  2018-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.